/Linear Heterobifunctional PEG Derivatives

Linear Heterobifunctional PEG Derivatives

Linear Heterobifunctional PEG Derivatives 2018-06-18T15:52:42+00:00

JenKem PEG RnDJenKem Technology provides high quality heterobifunctional polyethylene glycol derivatives (PEGs) with high purity and low polydispersity.

JenKem Technology’s heterobifunctional PEG derivatives are generally employed as crosslinking agents or as spacers between two different chemical entities. The PEG moiety in the heterobifunctional PEG derivatives provides water solubility, biocompatibility, and flexibility to the linker. Applications are especially geared towards the development of antibody drug conjugates (ADC’s). Linear heterobifunctional PEG derivatives have the following general structure:

X―PEG―Y

where X and Y are two different functional reactive groups.

JenKem Technology’s multi-arm heterofunctional PEG Derivatives are also useful as linkers for Antibody-Drug Conjugates. ADCs conjugated via heterobifunctional PEGs exhibit improved water solubility and PK/PD profile. Heterobifunctional PEG products with molecular weights and functional groups not listed in our online catalog may be available by custom synthesis. Please inquire at tech@jenkemusa.com about pricing and availability of custom synthesis PEGs. For global distribution, please visit link. To order directly from JenKem Technology:

 

 

PEG PRODUCT PURITY REACTIVITY DETAILS
≥95% Hydroxyl PEG Carboxyl (Hydroxyl PEG Acetic Acid, HO-PEG-CM, HO-PEG-COOH). COOH group is stable and can be activated [1, 2]
≥95% Hydroxyl PEG Succinimidyl Carboxymethyl Ester (HO-PEG-NHS). Crosslinking reagent, the activated form of HO-PEG-COOH [3, 4]
≥95% Hydroxyl PEG Propionic Acid (Hydroxyl PEG Propanoic Acid, HO-PEG-PA). COOH group is stable and can be activated
≥95% Hydroxyl PEG Succinimidyl Propionate (Hydroxyl PEG Succinimidyl Propanoate, HO-PEG-SPA). Crosslinking reagent, the activated form of HO-PEG-PA
≥95% Hydroxyl PEG Hexanoic Acid (HO-PEG-HA). COOH group is stable and can be activated
≥95% Hydroxyl PEG Amine (HO-PEG-NH2). NH2 group is stable and can be activated [8]
≥95% Thiol PEG Carboxyl (HS-PEG-COOH, Thiol PEG Acetic Acid, HS-PEG-CM). HS is thiol reactive, while COOH is stable and can be activated [5, 6]
≥95% Thiol PEG Succinimidyl Propionate (HS-PEG-SPA). HS is thiol reactive while COOH is stable and can be activated [42]
>90% Thiol PEG Succinimidyl Glutaramide (HS-PEG-SGA). Crosslinking PEG reagent. Longer hydrolysis half-life compared to the SCM NHS PEG ester. [7]
≥95% Thiol PEG Amine (HS-PEG-NH2). HS is thiol reactive and NH2 is stable and can be activated [9]
≥95% Amine PEG Carboxyl (NH2-PEG-COOH). Both COOH and NH2 groups are stable and can be activated [10, 11, 40, 41]
≥95% TBOC Amine PEG Hydroxyl (TBOC-PEG-OH). Crosslinking PEG reagent. Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [12]
≥95% TBOC Amine PEG Amine (TBOC-PEG-NH2). Crosslinking PEG reagent. Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [13]
≥95% TBOC Amine PEG Carboxyl (TBOC-PEG-COOH, TBOC-PEG-CM, TBOC PEG Acetic Acid). Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [15]
>90% TBOC Amine PEG SCM Ester (TBOC-PEG-SCM, TBOC-PEG-NHS, ). Crosslinking PEG for ADC development. Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine [18]
>90% TBOC Amine PEG Succinimidyl Propionate (TBOC-PEG-SPA). Crosslinking PEG for ADC development. Tert-butyloxycarbonyl (Boc) protection group can be removed by treatment with trifluoroacetic acid (TFA) or other common acids to provide a free amine
≥95% FMOC Amine PEG Hydroxyl (FMOC-PEG-OH) Crosslinking PEG reagent. The 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine
≥95% FMOC Amine PEG Amine (FMOC-PEG-NH2). Crosslinking PEG reagent. 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [14]
≥95% FMOC Amine PEG Carboxyl (FMOC-PEG-COOH, FMOC-PEG-CM, FMOC-PEG-Acetic Acid). The 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [16, 17]
>90% FMOC Amine PEG NHS Ester (FMOC-PEG-SCM, FMOC-PEG-NHS). The 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [19]
>90% FMOC Amine PEG Succinimidyl Propionate (FMOC PEG SPA). The 9-fluorenylmethoxycarbonyl (Fmoc) group can be removed by treatment with piperidine to release a free amine [19]
>90% Acrylate PEG NHS Ester (ACLT-PEG-NHS, ACLT-PEG-SCM). Light sensitive PEG, will crosslink with exposure to ultraviolet light [20-22]
>90% Acrylate PEG Succinimidyl Propionate (ACLT-PEG-SPA). Light sensitive PEG, will crosslink with exposure to ultraviolet light
≥95% Maleimide PEG Hydroxyl (MAL-PEG-OH). Maleimide is thiol reactive and Hydroxyl is stable [23]
≥95% Maleimide PEG Amine (MAL-PEG-NH2). Maleimide is thiol reactive and Amine is stable and can be activated [24]
≥95% Maleimide PEG Carboxyl (MAL-PEG-CM, MAL-PEG-COOH). Maleimide is thiol reactive and Carboxyl is stable and can be activated [25]
>90% Maleimide PEG NHS Ester, the activated form of MAL-PEG-COOH [26-31]
>90% Biotin PEG SCM Ester. Biotin can be attached to avidin-containing surfaces or molecules; NHS ester reacts with amine groups [32]
≥95% Biotin PEG Maleimide. Crosslinking reagent for ADC development. Biotin can be attached to avidin-containing surfaces or molecules; Maleimide group is thiol reactive [33]
≥95% Biotin PEG Succinimidyl Glutaramide. Biotin can be attached to avidin-containing surfaces or molecules; SGA has a longer hydrolysis half-life compared with SCM NHS Ester [38]
>90% OPSS PEG NHS Ester. Ortho-pyridyl disulfide (OPSS) is thiol reactive; NHS ester can be reacted with Amine groups [34]
>90% Azide PEG NHS Ester. The Azide group may be reduced to amine by hydrogenolysis; Click chemistry PEG reagent for reaction with alkynes [35]
≥95% Azide PEG Amine. The Azide group may be reduced to amine by hydrogenolysis; Click PEG reagent for reaction with alkynes [36]
≥95% Alkyne PEG Maleimide. Click PEG reagent for reaction with azides [37]

Monodisperse (Discrete) Heterobifunctional PEGs

Multiarm Heterobifunctional (3ARM, 4ARM, 6ARM and 8ARM PEGs) 

Linear PEG Raw Materials (Methoxy PEG Hydroxyl and Benzyl PEG Hydroxyl)

PEG RAW MATERIAL MAIN PEAK FRACTION BY GPC  POLYDISPERSITY BY GPC
≥95% ≤ 1.05-1.10
≥95% ≤ 1.05

 

References:
  1. Feldmann, D.P., et al., The impact of microfluidic mixing of triblock micelleplexes on in vitro in vivo gene silencing and intracellular trafficking, Nanotechnology, 2017, 28(22):224001.
  2. Jones, S.K, et al., Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance, Biomacromolecules, 2016, 17 (1), 76-87.
  3. Dutta, R., et al., Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice, Pharmaceutical research, 2017, 34(3):564-78.
  4. Chen, G., et al., KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy, Biomaterials, 2016, 97, p. 22-33.
  5. Mao, W., et al., Doxorubicin encapsulated clicked gold nanoparticle clusters exhibiting tumor-specific disassembly for enhanced tumor localization and computerized tomographic imaging, Journal of Controlled Release. 2018, 269: 52-62.
  6. Shi, H., et al., Tumor-targeting CuS nanoparticles for multimodal imaging and guided photothermal therapy of lymph node metastasis, Acta biomaterialia 2018, 72, pp.256-265.
  7. Lee, K., et al., Enhanced accumulation of theranostic nanoparticles in brain tumor by external magnetic field mediated clustering of magnetic nanoparticles, Journal of Industrial and Engineering Chemistry, 2017, 54, p. 389-397.
  8. Xu, Y., et al., Triphenylphosphonium-modified poly (ethylene glycol)-poly (ε-caprolactone) micelles for mitochondria-targeted gambogic acid delivery, International Journal of Pharmaceutics, 2017, 522(1):21-33.
  9. Li, J., et al., Octopod PtCu Nanoframe for Dual-Modal Imaging-Guided Synergistic Photothermal Radiotherapy, Theranostics 2018, 8(4), p.1042.
  10. Terracciano, M., et al., Gold decorated porous biosilica nanodevices for advanced medicine, Nanotechnology, 2018, 29(23), p.235601.
  11. Sanna, V., et al., Targeted nanoparticles encapsulating (−)-epigallocatechin-3-gallate for prostate cancer prevention and therapy, Scientific Reports, 2017, 7:41573.
  12. Yu, H., et al., Enzyme sensitive, surface engineered nanoparticles for enhanced delivery of camptothecin, Journal of Controlled Release, 2015, Volume 216, Pages 111-120.
  13. Ai, F., et al., An upconversion nanoplatform with extracellular pH-driven tumor-targeting ability for improved photodynamic therapy, Nanoscale, 2018, 10(9), pp.4432-4441.
  14. Soni, K.S., et al., Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer, Journal of Controlled Release, 2017, V. 264, P. 276-287.
  15. Chen, F., et al., Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA, Biomater. Sci., 2016,4, 167-182.
  16. Veiman, K.-L., et al., PEG shielded MMP sensitive CPPs for efficient and tumor specific gene delivery in vivo, Journal of Controlled Release 2015, 209: 238-247.
  17. Guarnieri, D., et al., Tumor‐activated prodrug (TAP)‐conjugated nanoparticles with cleavable domains for safe doxorubicin delivery, Biotechnology and Bioengineering 2015, 112(3): 601-611.
  18. Kuruvilla, S.P., et al., Effect of N-acetylgalactosamine ligand valency on targeting dendrimers to hepatic cancer cells, International journal of pharmaceutics, 2018, 545(1-2), pp.27-36.
  19. Zhang, J., et al., Liver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeutics, Biomaterials, Volume 70, November 2015, Pages 37-47.
  20. Post, A., et al., Introduction of sacrificial bonds to hydrogels to increase defect tolerance during suturing of multilayer vascular grafts, Acta Biomaterialia 2018, V. 69, p. 313-322.
  21. Shih, T.Y., et al., Injectable, Tough Alginate Cryogels as Cancer Vaccines, Advanced healthcare materials, 2018, p.1701469.
  22. Stukel, J.M., et al., The interplay of peptide affinity and scaffold stiffness on neuronal differentiation of neural stem cells. Biomedical Materials, 2018, 13(2), p.024102.
  23. Sarmanova, O.E., et al., A method for optical imaging and monitoring of the excretion of fluorescent nanocomposites from the body using artificial neural networks, Nanomedicine: Nanotechnology, Biology and Medicine, 2018, 14(4), pp.1371-1380.
  24. Khondee, S., et al., Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment, Current drug delivery, 2018, 15(3), pp.406-416.
  25. Wu, D., et al., RGD/TAT-functionalized chitosan-graft-PEI-PEG gene nanovector for sustained delivery of NT-3 for potential application in neural regeneration, Acta biomaterialia, 2018, 72, pp.266-277.
  26. Zhou, F., et al., Electrospun membranes of PELCL/PCL-REDV loading with miRNA-126 for enhancement of vascular endothelial cell adhesion and proliferation, Materials Science and Engineering: C 2018, V. 85, P. 37-46.
  27. Narmani, A., et al., Targeting delivery of oxaliplatin with smart PEG-modified PAMAM G4 to colorectal cell line: In vitro studies, Process Biochemistry 2018.
  28. Ruan, C., et al., Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma, Acta Pharmaceutica Sinica B 2018, V. 8, Issue 1, P. 85-96.
  29. Han, S., et al., A novel synergetic targeting strategy for glioma therapy employing borneol combination with angiopep-2-modified, DOX-loaded PAMAM dendrimer, Journal of drug targeting, 2018, 26(1), pp.86-94.
  30. Qi, H., et al., Exosomes separated based on the “STOP” criteria for tumor-targeted drug delivery, Journal of Materials Chemistry B, 2018, 6(18), pp.2758-2768.
  31. Li, H., et al., Dendron‐Grafted Polylysine‐Based Dual‐Modal Nanoprobe for Ultra‐Early Diagnosis of Pancreatic Precancerosis via Targeting a Urokinase‐Type Plasminogen Activator Receptor, Advanced healthcare materials, 2018, 7(5), p.1700912.
  32. Li ,M., Mapping Membrane Proteins on Cell Surface by AFM, Investigations of Cellular and Molecular Biophysical Properties by Atomic Force Microscopy, Nanorobotics, 2018, pp. 65-77.
  33. Khare, R., et al., Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors, J. Virology, 2012, 86(4) p: 2293-2301.
  34. Ye, J., et al., Cellular uptake mechanism and comparative in vitro cytotoxicity studies of monomeric LMWP-siRNA conjugate, Journal of Industrial and Engineering Chemistry 2018.
  35. Liu, L., et al., Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor growth and Promoting Immunity, Theranostics, 2018, 8(11), pp.2974-2987.
  36. Ma, H., et al., Dehydroascorbic Acid and pGPMA Dual Modified pH-Sensitive Polymeric Micelles for Target Treatment of Liver Cancer. Journal of pharmaceutical sciences 2018, 107(2), pp.595-603.
  37. Badkas, A., et al., Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin®-conjugated PLGA-PEG nanoparticles for drug delivery, Colloids and Surfaces B: Biointerfaces 2018, V. 162, P. 271-278.
  38. Ju, L., et al., Von Willebrand factor-A1 domain binds platelet glycoprotein Ibα in multiple states with distinctive force-dependent dissociation kinetics, Thrombosis Research, 2015, Volume 136, Issue 3, Pages 606-612.
  39. Alpsoy, L., et al., Synthesis and Characterization of Carboxylated Luteolin (CL)-Functionalized SPION, Journal of Superconductivity and Novel Magnetism, 2017.
  40. Clawson, G.A., et al., A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma, Nucleic acid therapeutics, 2017, 27(1):23-35.
  41. Clawson, G.A., et al., A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma, Nucleic acid therapeutics, 2017, 27(1):23-35.
  42. Li, H., et al., Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma, Biomaterials, 2017.

Founded in 2001 by recognized experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to on-site manufacturing from ethylene oxide, enabling facile traceability for GMP regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.